Analysts Anticipate Vanda Pharmaceuticals Inc. (VNDA) Will Announce Quarterly Sales of $49.80 Million
Equities analysts predict that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will report sales of $49.80 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Vanda Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $48.40 million and the highest estimate coming in at $51.00 million. Vanda Pharmaceuticals reported sales of $41.34 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 20.5%. The firm is expected to announce its next quarterly earnings results on Tuesday, November 6th.
According to Zacks, analysts expect that Vanda Pharmaceuticals will report full year sales of $193.00 million for the current fiscal year, with estimates ranging from $189.00 million to $196.00 million. For the next financial year, analysts anticipate that the firm will report sales of $237.77 million per share, with estimates ranging from $223.00 million to $261.30 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, August 1st. The biopharmaceutical company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.14. The firm had revenue of $47.40 million for the quarter, compared to the consensus estimate of $47.28 million. Vanda Pharmaceuticals had a return on equity of 0.68% and a net margin of 0.73%. The firm’s quarterly revenue was up 12.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.03 EPS.
Institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new stake in Vanda Pharmaceuticals during the 1st quarter worth approximately $117,000. Trexquant Investment LP acquired a new stake in Vanda Pharmaceuticals during the 2nd quarter worth approximately $212,000. Hartford Investment Management Co. acquired a new stake in Vanda Pharmaceuticals during the 2nd quarter worth approximately $214,000. NumerixS Investment Technologies Inc lifted its position in Vanda Pharmaceuticals by 92.9% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 11,835 shares of the biopharmaceutical company’s stock worth $227,000 after acquiring an additional 5,700 shares during the period. Finally, Xact Kapitalforvaltning AB acquired a new stake in Vanda Pharmaceuticals during the 2nd quarter worth approximately $240,000. 93.56% of the stock is owned by institutional investors.
NASDAQ:VNDA traded up $0.35 during mid-day trading on Thursday, reaching $19.45. 584,700 shares of the stock were exchanged, compared to its average volume of 587,057. The company has a market capitalization of $1.04 billion, a PE ratio of -55.57 and a beta of 0.52. Vanda Pharmaceuticals has a 1 year low of $11.90 and a 1 year high of $23.35.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Recommended Story: Should I follow buy, hold and sell recommendations?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.